Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on MERCK & CO., INC.
09/08MERCK : Berenberg Bank Adjusts Merck & Company PT to $86 From $88, Maintains Hold Rating
MT
09/07MERCK : Morgan Stanley Downgrades Merck & Company to Equalweight from Overweight, Adjusts ..
MT
09/07ANALYST RECOMMENDATIONS : Amgen, Banner, Merck, Oracle, Phoenix...
07/30MERCK : Goldman Sachs Adjusts Price Target for Merck to $104 From $102, Maintains Buy Rati..
MT
07/30MERCK : SVB Leerink Adjusts Price Target on Merck & Company to $101 From $99, Maintains Ou..
MT
07/28ANALYST RECOMMENDATIONS : Flutter, Hasbro, MGM Resort, Microsoft Vodafone...
07/27MERCK : Truist Assumes Merck & Company at Buy Rating With $92 Price Target
MT
07/14MERCK : RBC Lifts Price Target on Merck to $80 From $75 Ahead of Q2 Results, Reiterates Se..
MT
06/09MERCK : JPMorgan Adjusts Merck's Price Target to $100 From $105, Maintains Overweight Rati..
MT
06/08MERCK : Price Target From RBC Cut to $75 From $77 to Reflect Organon Spinoff, Sector Perfo..
MT
06/07MERCK : Truist Securities Adjusts Merck's Price Target to $93 From $96, Maintains Buy Rati..
MT
06/03MERCK : SVB Leerink Adjusts Merck & Co.'s Price Target to $99 from $102, Keeps Outperform ..
MT
05/20MERCK : Argus Research Downgrades Merck & Company to Hold Rating From Buy
MT
04/30MERCK : RBC Capital Adjusts Merck & Company PT to $77 From $79, Maintains Sector Perform R..
MT
2020MERCK : Bernstein Reinstates Merck & Co. at Outperform with $95 Price Target
MT
2020MERCK : Expects Nearly $2 Billion Covid-19 Revenue Impact in 2020
DJ
2020Pharma Companies Split on Coronavirus Vaccine Pricing Plans
DJ
2020MERCK & CO INC : RBC gives a Neutral rating
MD
2019Bristol-Myers posts better-than-expected results, Opdivo growth slows
RE
2019MERCK & CO INC : Goldman Sachs remains Neutral
MD
2019MERCK & CO INC : JP Morgan remains Neutral
MD
2019AstraZeneca Imfinzi combination fails advanced lung cancer study
RE
2019Elanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
2019Elanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
2019Eliquis, Orencia sales propel Bristol-Myers to strong second quarter
RE
2019Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals
RE
2019Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals
RE
2019Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
RE
2018Pfizer to replace longtime CEO Read with veteran Bourla
RE
2018Pfizer to replace longtime CEO Read with veteran Bourla
RE
2018Roche steps up efficiency drive to take sting out of biosimilars
RE
2018Roundup cancer verdict sends Bayer shares sliding
RE
2018Roundup cancer verdict sends Bayer shares sliding
RE
2018Clamour for GSK shingles shot points to bigger profits
RE
2018AstraZeneca cancer drug hits second goal by extending survival
RE
2018Keytruda sales power Merck to quarterly beat
RE
2018Keytruda sales power Merck to quarterly beat
RE
2018GlaxoSmithKline prescribes commercial reboot for pharma division
RE
2018GlaxoSmithKline prescribes commercial reboot for pharma division
RE
2018Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
2018U.S. tax change to help Roche's 2018 profit growth outpace sales
RE
2017Roche drug cocktail doubles chance of holding lung cancer at bay
RE
2017GSK wins U.S. shingles vaccine approval, UK nod for gene therapy
RE
2017Germany's Merck hires JP Morgan to sell consumer health
RE
2017AstraZeneca shares surge after key drug shows promise in lung cancer trial
RE
2017MERCK : 2017 forecast reassuring; full-speed ahead with Keytruda
RE
2017Bristol-Myers lung cancer delay slams shares, keeps Merck in lead
RE
2017Bristol-Myers shares fall on lung cancer timeline setback
RE
2016Pharma, biotech shares soar as Trump win calms pricing talk
RE
2016Pharma, biotech shares soar as Trump win calms pricing talk
RE
2016Drugmakers under fire for possible U.S. price fixing
RE
2016Bristol lung-cancer setback puts rival Merck drug in driver seat
RE
2016MERCK : China's drugs watchdog struggles as senior staff lured away by industry
RE
2016BRISTOL MYERS SQUIBB : Merck sales disappoint as Januvia, Remicade fall short
RE
2016Merck gives cautious 2016 outlook as sales of top medicines lag
RE
2015Merck profit tops estimates on strong diabetes, cancer drug sales
RE
2015Wall St. ends lower with oil prices, renewed Greece worries
RE
2014Pfizer dampens Astra bid hopes with German Merck cancer deal
RE
2014ASTRAZENECA : touts independence as Nexium drug keeps on giving
RE
2014AstraZeneca gets sales boost as Nexium drug keeps on giving
RE
2014Bayer third-quarter adjusted profit gains slightly on strong crop chemicals
RE
2014MERCK : quarterly profit beats estimates; shares gain
RE
2014Bayer signs $14.2 billion acquisition loan
RE
2014Bayer wins Merck & Co's $14 billion consumer unit auction
RE
2014Bayer wins Merck & Co's $14 billion consumer unit auction
RE
2014EXCLUSIVE : Abbott taps Morgan Stanley to sell mature products - sources
RE
2014AstraZeneca cancer pipeline seen as draw for Pfizer
RE
2014Reckitt Benckiser sees more sales growth, names chairman for pharma unit
RE
2014Trade group seeks more U.S. pressure on India over patent protection
RE
2014AstraZeneca profits heading south as patent losses bite
RE
2014Ablynx agrees Merck cancer deal worth up to 1.7 billion euros
RE
2013GSK cancer vaccine disappoints in melanoma trial
RE
2013WALL STREET WEEK AHEAD : Central banks, data to steer investors
RE
2013Merck to pay $688 million to settle Enhance lawsuits
RE
2012Pfizer plans animal health IPO
RE
1  2Next
Upcoming event on MERCK & CO., INC.
10/28/21